IQVIA Holdings Inc.

XNYSHealth care

Last traded price · USD

$262.59

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $262.59
Volume: 2
Day's high: —
Day's low: —

In brief

IQVIA Holdings Inc. is a health care company listed on the New York Stock Exchange, valued at about $43.27B.
Its shares closed at $262.59 on 3 Nov 2026, up 22.8% over the past year.
From India you can buy IQV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy IQVIA Holdings Inc. (IQV) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IQV share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IQV options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −1.3% (SPY −2.6%, XLV +9.9%). 3 months: +15.1% (SPY −2.2%, XLV +13.5%). 1 year: +22.8% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IQV, SPY and XLV · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 3 Nov 2026 close of $262.59 was 1.3% below its 50-day average ($266.11) and 25.2% above its 200-day average ($209.73). It has closed above the 200-day for 88 sessions, since 1 Jul 2026. The 50-day average crossed above the 200-day on 6 Aug 2026, 62 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
83% of the way up its 52-week range
Closed at $262.59 on 3 Nov 2026: 7.7% below the 52-week high of $284.50 (27 Oct 2026) and 70.0% above the low of $154.50 (30 Apr 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Short interest at 1.8% of shares outstanding
3.0M shares were sold short at the 15 Oct 2026 settlement, 1.8% of the 164.8M shares outstanding; covering them would take 2.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−1.3%

6 months+48.8%

1 year+22.8%

5 years+3.1%

Newswire

About

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Website

Notable moves

July 28, 2026
+13.94%
July 22, 2025
+17.88%
February 14, 2024
+13.10%

Newswire

About

Website

Notable moves

July 28, 2026
+13.94%
July 22, 2025
+17.88%
February 14, 2024
+13.10%

IQVIA Holdings Inc.

XNYSHealth care

Last traded price · USD

$262.59

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $262.59
Volume: 2
Day's high: —
Day's low: —

In brief

IQVIA Holdings Inc. is a health care company listed on the New York Stock Exchange, valued at about $43.27B.
Its shares closed at $262.59 on 3 Nov 2026, up 22.8% over the past year.
From India you can buy IQV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy IQVIA Holdings Inc. (IQV) shares from India?

Do I need the price of a whole IQV share to invest?

How much can I invest in US stocks in a year?

Can I trade IQV options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −1.3% (SPY −2.6%, XLV +9.9%). 3 months: +15.1% (SPY −2.2%, XLV +13.5%). 1 year: +22.8% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IQV, SPY and XLV · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 3 Nov 2026 close of $262.59 was 1.3% below its 50-day average ($266.11) and 25.2% above its 200-day average ($209.73). It has closed above the 200-day for 88 sessions, since 1 Jul 2026. The 50-day average crossed above the 200-day on 6 Aug 2026, 62 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
83% of the way up its 52-week range
Closed at $262.59 on 3 Nov 2026: 7.7% below the 52-week high of $284.50 (27 Oct 2026) and 70.0% above the low of $154.50 (30 Apr 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Short interest at 1.8% of shares outstanding
3.0M shares were sold short at the 15 Oct 2026 settlement, 1.8% of the 164.8M shares outstanding; covering them would take 2.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−1.3%

6 months+48.8%

1 year+22.8%

5 years+3.1%

Newswire

About

Website

Notable moves

July 28, 2026
+13.94%
July 22, 2025
+17.88%
February 14, 2024
+13.10%

Newswire

About

Website

Notable moves

July 28, 2026
+13.94%
July 22, 2025
+17.88%
February 14, 2024
+13.10%

IQVIA Holdings Inc.

IQVIA Holdings Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

83% of the way up its 52-week range

Short interest at 1.8% of shares outstanding

IQVIA Holdings Inc.

IQVIA Holdings Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

83% of the way up its 52-week range

Short interest at 1.8% of shares outstanding